Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol

Investigational New Drugs

Volumn 14, Issue 3, 1996, Pages 287-294

  Mendelsohn, Laurane G ^a   Shih, Chuan ^a   Schultz, Richard M ^a   Worzalla, John F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antifolate; Antimetabolite; Antitumor; Cytotoxicity; GAR formyltransferase

Indexed keywords

2',5' THIENYL 5,10 DIDEAZATETRAHYDROFOLIC ACID; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; LOMETREXOL; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CANCER INHIBITION; COLON CANCER; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; LIVER; MOUSE; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY; TUMOR XENOGRAFT;

ACYLTRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; MICE; MICE, INBRED C3H; MICE, NUDE; MOLECULAR STRUCTURE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029802509     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00194532     Document Type: Article

References (28)

1. Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG: Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetra hydroaminopterin. J Med Chem 28:914-921, 1985
2. Beardsley GP, Moroson BA, Taylor EC, Moran RG: A new antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333, 1989
3. Shih C, Grindey GB, Houghton PJ, Houghton JA: In vivo antitumor activity of 5,10-dideazatetrahydrofolic acid (DDATHF) and its diastereomeric isomers. Proc Am Assoc Cancer Res 29:283, 1988
4. Beardsley GP, Pizzorno G, Russello O, Cashmore AR, Moroson BA, Cross AD, Wildman D: Biochemical pharmacology of deazatetrahydrofolates. In: Curtius HC, Ghisla S, Blau N (eds) Chemistry and Biology of Pteridines. Walter de Gruyter and Co., Berlin, 1989, pp 1001-1008
5. Ray MS, Muggia FM, Leichman GC, Nelson RL, Dyke RW, Moran RG: Phase I study of 6(R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85:1154-1159, 1993
6. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB: Augmentation of the therapeutic activity of lometrexol ((6-R)5,10-dideazatetrahydrofolate) by oral folic acid. Cancer Research (in press) 1996
7. Habeck LL, Worzalla JF, Shih C, Gossett LS, Self TD, Rutherford P, Mendelsohn LG: Deposition and polyglutamate distribution of 14C-lometrexol and its thiophene analogue n murine liver and C3H mammary tumor. Proc Amer Assoc Cancer Res 36:378, 1995
8. Gates SB, Mendelsohn LG, Shackelford KA, Habeck LL, Kursar JD, Rutherford PG, Gossett LS, Worzalla JF, Shih C, Grindey GB: Characterization of folate receptor from normal and neoplastic tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res 2:1135-1141, 1996
9. Worzalla JF, Self TD, Theobald KS, Rutherford PG, Gossett LS, Shih C, Mendelsohn LG: Antitumor therapeutic index of LY309887 is improved with increased folic acid supplementation in mice maintained on a folate deficient diet. Proc Amer Assoc Cancer Res 37:383, 1996
10. Worzalla JF, Ehlhardt WJ, Seitz DE, Seymour PD, Allen RH, Mendelsohn LG, Shih C: Elevation of homocysteine in plasma of mice as a marker for dietary folic acid status. Proc Amer Assoc Cancer Res 37:384, 1996
11. Mendelsohn LG, Gates SB, Habeck LL, Shackelford KA, Worzalla JF, Shih C, Grindey GB: The role of dietary folates in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul 36:365-381, 1996
12. Einhorn J, Reizenstein P: Metabolic studies on folic acid in malignancy. Cancer Res 26:340-343, 1966
13. Saleh AM, Pheasant AE, Blair JA, Allan RN, Walters J: Folate metabolism in man: the effect of malignant disease. Br J Cancer 46:346-353, 1982
14. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR: Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,7-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479-1486, 1996
15. Shih C, Taylor EC, Grindey GB, Moran RG, Gossett LS, Harrington PM: Synthesis and structure-activity relationship studies of 5,10-dideazatetrahydrofolic acid (DDATHF). In: Curtius HC, Ghisla S, Blau N (eds) Chemistry and Biology of Pteridines. Walter de Gruyter and Co., Berlin, 1989, pp 1035-1038
16. Habeck LL, Leitner TA, Shackelford KA, Gossett LS, Schultz RM, Andis SL, Shih C, Grindey GB, Mendelsohn LG: A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res 54:1021-1026, 1994
17. Habeck LL, Moran RG, Shih C, Gossett LS, Leitner TA, Schultz RM, Andis S, Mendelsohn LG: Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate and related analogs. Molecular Pharmacol 48:326-333, 1995
18. Montero C, Llorente P: Single step LC method for determination of folylpolyglutamate synthetase activity and separation of polyglutamates. Chromatographia 37:73-78, 1993
19. Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. One Res 5:223-228, 1993
20. Worzalla JF, Bewley JR, Grindey GB: Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 8:241-251, 1990
21. McGuire JJ, Bertino JR: Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 39:19-38, 1981
22. Ward WHJ, Kimbell R, Jackman AL: Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharm 43:2029-2031, 1992
23. Wang X, Shen F, Freisheim JH, Gentry IE, Ratnam M: Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 44:1898-1901, 1992
24. Campbell IG, Jones TA, Foulkes WD, Trowsdale J: Folate-binding protein is a marker for ovarian cancer. Cancer Res 51:5329-5338, 1991
25. Ross JF, Chaudhuri PK, Ratnam M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 73:2432-2434, 1994
26. Muindi JRF, Young CW, Shih C: Specific and sensitive high-performance liquid chromatographic methods with fluorescence detection for measurement of lometrexol and its polyglutamates in biologic samples. J Chromat 621:55-64, 1993
27. Wedge SR, Laohavinji GA, Taylor GA, Newell DR: Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate(lometrexol) in human plasma and urine by high-performance liquid chromatography. J Chromat B 663:327-335, 1995
28. Worzalla JF, Rutherford PG, Self TD, Seymour PD, Theobald KS, Mendelsohn LG, Gossett LS, Shih C, Schultz RM, Grindey GB: In vivo antitumor activity of LY309887, a new antifolate inhibitor of glycinamide ribonucleotide formyl transferase. Proc Amer Assoc Cancer Res 36:378, 1995